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ABSTRACT
Background. To improve the prognosis of patients after
resection of pancreatic cancer, the most appropriate and
efﬁcient treatment should be provided to speciﬁc subsets of
patients. Our aim was to identify promising microRNAs as
markers to predict responses to gemcitabine in patients
with resected pancreatic cancer.
Methods. Two gemcitabine-resistant pancreatic cancer cell
lines were established, and global microRNA expression
analyseswasperformedbyquantitativereversetranscription–
polymerasechainreaction(qRT-PCR).ElevenmiRNAswere
selectedasputativepredictivemarkersandanalyzedbymeans
of macrodissected formalin-ﬁxed, parafﬁn-embedded sam-
ples obtained from 90 patients with or without gemcitabine
treatment after resection of pancreatic cancer.
Results. We identiﬁed 24 microRNAs whose expression
was altered in gemcitabine-resistant cells. qRT-PCR anal-
yses showed that patients with high miR-142-5p and miR-
204 expression had signiﬁcantly longer survival times than
those with low miR-142-5p (P = 0.0077) and miR-204
(P = 0.0054) expression in the gemcitabine-treated group.
This was not seen in the nontreated group. Multivariate
analyses showed that miR-142-5p expression was an
independent prognostic marker only in patients treated with
gemcitabine (P = 0.034).
Conclusions. miR-142-5p is a promising predictive mar-
ker for gemcitabine response in patients with resected
pancreatic cancer.
Pancreatic cancer is the fourth most common cause of
tumor-related death in the industrialized world.
1,2 Only
10–20% of pancreatic cancer patients are candidates for
surgery at the time of presentation, and fewer than 20%
of patients who undergo curative resection are alive
after 5 years.
3,4 A few recent reports have described the
successful use of adjuvant chemotherapies such as 5-ﬂuo-
rouracil and gemcitabine.
5,6 However, not all patients
beneﬁt from such adjuvant chemotherapy, and we cannot
predict which patients will beneﬁt most from this treat-
ment. Therefore, to improve the prognosis of patients with
resected pancreatic cancer, we need to identify speciﬁc
markers that can predict responses to adjuvant therapy.
Such a personalized therapy, based on the predictive
markers, may provide the most appropriate and efﬁcient
treatment for a speciﬁc subset of patients.
Gemcitabine is a deoxycytidine analog with antitumor
activity that bears a resemblance, both structurally and
metabolically, to arabinosyl cytosine.
7 Gemcitabine is
widely accepted as the ﬁrst-line treatment for patients with
advanced or resected pancreatic cancer.
6,8 However, recent
reports showed that the complete plus partial response rate
and the disease control rate in advanced pancreatic cancer
are 8.0–13.5% and 49.2–62.1%, respectively, even with
combination-treatment arms.
9,10 The data suggest that
approximately half of patients with resected pancreatic
cancer do not beneﬁt from gemcitabine-based combination
therapies. Therefore, predictive markers are needed to
select those patients who may beneﬁt most from gemcita-
bine-based therapy. So far, research into the mechanism of
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candidate predictive markers. These include genes related
to gemcitabine metabolism and transport, such as deoxy-
cytidine kinase, ribonucleotide reductase, and human
equilibrative nucleoside transporter-1.
11,12 However, the
usefulness of such markers in a clinical setting remains
unclear because of difﬁculties in evaluating their protein or
mRNA levels. Even when well-established methods are
used, immunohistochemical evaluation and its interpreta-
tion are different between laboratories.
13 Also, accurate
quantitative analyses of mRNA from clinical samples are
often difﬁcult as a result of degradation. Therefore, we
need more reliable methods-based biomarkers to predict
responses to gemcitabine.
MicroRNAs (miRNAs) are small noncoding RNA gene
productsofapproximately22ntthatarefoundinavarietyof
organisms. They play key roles in regulating the translation
and degradation of mRNAs through base pairing to partially
complementary sites, predominantly in the 30-untranslated
regions of mRNAs.
14,15 Because microRNAs are well pre-
served, even in formalin-ﬁxed, parafﬁn-embedded (FFPE)
samples, the quantitative analysis of miRNA in many types
of clinical sample is accurate and reliable.
16,17 Therefore,
miRNAs are promising molecular markers.
There is increasing evidence that miRNAs are mutated
or differentially expressed in many types of cancers, and
thus are also potential diagnostic markers.
18–20 The
expression levels of several miRNAs, such as miR-21,
miR-196a-2, miR-155, and miR-210 in pancreatic cancer,
are known to correlate with a poor prognosis.
19,21,22 Thus,
there is a possibility that speciﬁc miRNAs that can be used
as predictive markers for a gemcitabine response exist.
Here, to identify predictive markers, we established two
gemcitabine-resistant pancreatic cancer cell lines and per-
formed global miRNA expression analyses. We then
further investigated 11 selected miRNAs as potential pre-
dictive markers using macrodissected FFPE samples
derived from 90 patients with resected pancreatic cancer.
MATERIALS AND METHODS
Cell Lines and Establishment of Gemcitabine-Resistant
Cells
Two human pancreatic cancer cell lines, SUIT-2 and
CAPAN-1 (the gift of Dr. H. Iguchi, National Shikoku
Cancer Center, Matsuyama, Japan), were used in this study.
Gemcitabine-resistant cells were generated by exposing
these cell lines to gradually increasing concentrations of
gemcitabine. The initial concentration of gemcitabine was
1 nM, which did not seem to affect the proliferation of
either the SUIT-2 or CAPAN-1 cells. When the cells had
adapted to the drug, the concentration of gemcitabine was
gradually increased by 10–100 nM per week to a ﬁnal
concentration of 200 nM (SUIT-2) and 1 lM (CAPAN-1).
Gemcitabine was dissolved in phosphate-buffered saline
and added to the cell culture media.
Propidium Iodide Assay
Cell proliferation was evaluated by measuring the
ﬂuorescence intensity of propidium iodide as described
previously.
23 The ﬂuorescence intensity corresponding to
the total cells was measured with a CytoFluor multiwell
plate reader (PerSeptive Biosystems, Framingham, MA,
USA). The results were converted to percentage survival
rates by comparing treated cells with untreated cells.
miRNA Expression Proﬁling
Expression proﬁles for the 365 mature miRNAs were
obtained by quantitative polymerase chain reaction (qPCR)
using the TaqMan Array Human MiRNA (TLDA) or
TaqMan MiRNA Assays (Applied Biosystems; ABI) on an
ABI Prism 7900HT according to the manufacturer’s
instructions. Mature miRNAs were normalized to RNU44
and are expressed as fold changes relative to controls.
Patients and Pancreatic Tissues
From 1992 through 2008, a total of 104 patients
underwent pancreatic resection for pancreatic cancer at the
Department of Surgery and Oncology, Kyushu University
Hospital (Fukuoka, Japan). Survival was measured from
the time of pancreatic resection, and death was the end
point. The follow-up data for 103 cases were available.
Thirteen of the 103 patients were excluded from the present
study because they had received combination therapy with
gemcitabine and other chemotherapeutic agents such as
S1(tegafur/gimestat/potassium oxonate).
Our ﬁnal study series consisted of 90 patients with
resected pancreatic cancer with available follow-up data.
The patients (57 men and 32 women) had a median age of
65 years (range, 36–86 years). The median observation
time for overall survival was 14.7 months, ranging
0.5–108 months. Sixty-three patients died during follow-
up; the other patients were alive and censored.
All resected specimens were ﬁxed in formalin and
embedded in parafﬁn for pathological diagnosis. All tissues
adjacent to the specimens were evaluated histologically
accordingtothecriteriaoftheWorldHealthOrganization.
24
Diagnoses were conﬁrmed independently by two patholo-
gists with regard to the pathological features of all cases.
Tumor stage was assessed according to the International
Union Against Cancer classiﬁcation.
25 Clinicopathological
2382 K. Ohuchida et al.characteristicsofthetumorsareshowninTable 1.Thestudy
was approved by the Ethics Committee of Kyushu Univer-
sity and was conducted according to the Ethical Guidelines
for Human Genome/Gene Research enacted by the Japanese
government and the Helsinki Declaration.
Macrodissection
After a review of representative hematoxylin and eosin-
stained slides, 4–7 sections (5 lm thick) were cut from
FFPE blocks for macrodissection. Adjacent normal tissues,
including normal acinar tissues and adipose tissues, in the
sections were removed macroscopically with a scalpel.
Only the cancerous parts were used for the isolation of
miRNA.
Isolation of miRNA
miRNA was extracted from the macrodissected FFPE
samples with the RNeasy FFPE kit (Qiagen, Tokyo, Japan)
using a method modiﬁed from the manufacturer’s
instructions. Brieﬂy, macrodissected FFPE sections were
deparafﬁnized with xylene, washed with ethanol, and dried.
Lysis buffer and proteinase K were added to the dried
sections. The sections were incubated and Binding buffer
was then added to the lysate and transferred to a gDNA
Eliminator spin column (Qiagen) to remove genomic DNA.
After eliminating DNA, 100% ethanol was added to the
ﬂow-through. After mixing, the samples were transferred to
an RNeasy MinElute column (Qiagen), which binds total
RNA. After washing, the puriﬁed RNA was eluted with
50 ll of RNase-free water.
Quantitative Reverse Transcription–Polymerase Chain
Reaction
Quantitative reverse transcription–polymerase chain
reaction (qRT-PCR) was performed in a Chromo4 Real-
Time PCR Detection System (Bio-Rad Laboratories,
Hercules, CA, USA) using TaqMan MicroRNA Reverse
Transcription Kit and TaqMan Universal PCR Master Mix
(Applied Biosystems, Tokyo, Japan). For the measurement
of miRNA expression, we performed two-step qRT-PCR
with speciﬁc primers for the indicated miRNAs (designed
by Applied Biosystems) following the manufacturer’s
protocol. Each sample was run in triplicate. The level of
miRNA expression was calculated from a standard curve
constructed by using small RNAs from CAPAN-1 cells.
The expression levels of the indicated miRNAs were nor-
malized to those of RNU6B. The accuracy and integrity of
the PCR products were conﬁrmed with an Agilent 2100
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA,
USA).
Statistical Analysis
A data mining technique provided by the SAS Institute
was used to split gene expression in high- and low-level
groups on the basis of a platform that recursively partitions
data according to a relationship between the X and Y val-
ues, creating a tree of partitions (recursive descent partition
analysis).
26 By searching all possible cuts, it ﬁnds a set of
cut points of X values (gene expression) that best predict
the Y value (survival time). These data splits are done,
recursively forming a tree of decision rules until the desired
ﬁt is reached; the most signiﬁcant split is determined by
the largest likelihood ratio chi-square statistic. In either
case, the split is chosen to maximize the difference in
the responses between the two branches of the split.
TABLE 1 Correlation between median OS and clinical and patho-
logical factors in patients with resected pancreatic cancer
Factor n OS (95% CI) P value
Age 0.675
C65 years 47 19 (13.07–27)
\64 years 42 19 (12–26)
Sex 0.7544
Male 57 23 (13.07–30.17)
Female 32 14 (10–24.2)
pT category 0.0019
pTl/pT2/pT3 55 23 (16.30–43)
p4 33 12 (9.43–19)
pN category 0.0070
pN0 26 43 (16.93–)
pN1 62 13.27 (11.6–22)
Histological grade 0.0804
G1 19 31 (9–)
G2 33 23 (14–30.16)
G3 35 12 (10–23)
Residual tumor \0.0001
R0 53 26 (19–45)
R1 34 12 (9–13.73)
Vessel invasion 0.0204
Positive 57 13.73 (12–23)
Negative 31 27 (15–)
Lymphatic invasion 0.3004
Positive 76 15 (12–24.2)
Negative 18 27 (14.53–)
Neural invasion 0.6849
Positive 73 16.93 (13.07–26)
Negative 15 23 (4.7–)
Adjuvant therapy 0.0382
Yes 59 23 (14.53–30.17)
No 30 12 (7.7–24.2)
OS overall survival, CI conﬁdence interval
miRNA and Gemcitabine Response 2383Categorical variables were compared by a chi-square test
(Fisher’s exact probability test). Survival curves were
constructed using the Kaplan-Meier product-limit method
and compared by the log rank test. To evaluate the inde-
pendent prognostic factors associated with patient survival
(with or without gemcitabine treatment), multivariate Cox
proportional hazard regression analysis was used, with
miR-142-5p expression, miR-34a expression, pN status,
and/or residual tumor status (R factor) as covariates. Sta-
tistical signiﬁcance was deﬁned as a P value of\0.05. All
statistical analyses were performed by JMP 7.01 software
(SAS Institute, Cary, NC, USA).
RESULTS
Establishment of Gemcitabine-Resistant Pancreatic
Cancer Cells
Gemcitabine-resistant SUIT-2 and CAPAN-1 cells
were generated by exposure to gradually increasing con-
centrations of gemcitabine. The ﬁnal concentration of
gemcitabine was 200 nM for SUIT-2 cells and 1 lM for
CAPAN-1 cells. The viability of the parental SUIT-2 cells
signiﬁcantly decreased to less than 20% after treatment
with 10 nM gemcitabine, while the viability of gemcita-
bine-resistant SUIT-2 cells remained unchanged after
treatment with 10 nM gemcitabine. The viability of the
parental CAPAN-1 cells signiﬁcantly decreased to less than
10% after treatment with 1 lM gemcitabine, while the
viability of gemcitabine-resistant CAPAN-1 cells remained
unchanged after treatment with 1 lM gemcitabine.
miRNA Differentially Expressed between Parent
and Gemcitabine-Resistant Cells
We used the TaqMan miRNA array to obtain the 365
miRNA expression proﬁles from the parent and gemcita-
bine-resistant pancreatic cancer cell lines. The results show
that the expression of 10 miRNAs was more than 2-fold
higher in both SUIT-2 and CAPAN-1 gemcitabine-resistant
cells compared with the parental cells. We also identiﬁed
14 miRNAs in both SUIT-2 and CAPAN-1 gemcitabine-
resistant cells that were downregulated to less than 30% of
that in the parental cells.
To conﬁrm our TaqMan miRNA array data, we sub-
jected 11 of the differentially expressed miRNAs (5
upregulated miRNAs: miR-9, miR-27a, miR-424, miR-
449b, and miR-34a; 6 downregulated miRNAs: miR-152,
miR-181c, miR-518b, miR-125a, miR-142-5p, and miR-
204), which were selected on the basis of expression levels
and fold changes as promising candidate of clinical
markers, to triplicate qRT-PCR analysis, and obtained
consistent results (data not shown).
Analysis of miRNA Expression in Relation to Survival
Time of Patients with Pancreatic Cancer after Curative
Resection
Conventional prognostic factors, such as pT category,
pN category, R factor, positive vessel invasion, and adju-
vant therapies, including 5-ﬂuorouracil or gemcitabine,
reached signiﬁcance for overall survival (Table 1). We also
found that the patients treated with gemcitabine had a
better prognosis than those without, although the difference
was not signiﬁcant (P = 0.058).
Next, to investigate the correlation between gemcitabine
response and miRNA expression identiﬁed by miRNA
expression proﬁling, patients with resected pancreatic
cancer were divided into two groups: patients who were
treated with gemcitabine and patients who were not.
Within each group, we investigated the correlation between
the expression levels of the 11 miRNAs identiﬁed by
miRNA expression proﬁling and the prognosis of patients
with resected pancreatic cancer. miRNA expression was
also divided into high- and low-level groups by recursive
descent partition analysis, as described by Hoffmann
et al.
26
First, we investigated the correlation between prognosis
and the six downregulated miRNAs: miR-152, miR-181c,
miR-518b, miR-125a, miR-142-5p, and miR-204. For the
gemcitabine group, the high miR-142-5p and miR-204
patients had a signiﬁcantly longer survival time than the
low miR-142-5p and miR-204 patients (Figs. 1 and 2,
P = 0.0077 for miR-142-5p; P = 0.0054 for miR-204).
The median survival time was 45 months and 33 months,
respectively, for the high miR-142-5p and high miR-204
patients, and 16.3 months in both the low miR-142-5p and
low miR-204 patients (Table 2). We also found that the
high miR-125a patients had signiﬁcantly longer survival
times than the low miR-125a patients when the Wilcoxon
test was used (P = 0.035), although the difference was not
statistically signiﬁcant when the log rank test was used
(Table 2, P = 0.085). However, for the nongemcitabine
group, there were no differences in the survival times
between the high and low miR-142-5p, miR-204, or miR-
125a patients (Table 2). Analysis of both the gemcitabine
and nongemcitabine groups did not revealed any signiﬁcant
differences in survival time between the high and low miR-
152, miR-181c, and miR-518b patients (data not shown).
Next, we investigated the correlation between prognosis
and the six upregulated miRNAs: miR-9, miR-27a, miR-
424, miR-449b, and miR-34a. For the nongemcitabine
group, the high miR-34a patients had a signiﬁcantly longer
survival times than the low miR-34a patients (Table 2,
P = 0.012), while there were no signiﬁcant differences in
survival time between the high and low miR-34a patients in
the gemcitabine group (Table 2, P = 0.175). The median
2384 K. Ohuchida et al.survival time was 16.9 months in the high miR-34a
patients and 8.5 months in the low miR-34a patients in
the nongemcitabine group (Table 2). We also found no
signiﬁcant differences in survival between the high and low
miR-9, miR-27a, miR-424, and miR-449b patients in the
gemcitabine and nongemcitabine groups (data not shown).
Multivariate Analysis of miR-142-5p and miR-34a
Expression in Relation to Survival Time of Patients
with or without Gemcitabine Treatment after Curative
Resection
In three miRNAs identiﬁed as potential prognostic
markers in the gemcitabine group, miR-142-5p was the best
candidate and was the most speciﬁc for the gemcitabine
group compared with the nongemcitabine group. Therefore,
we focused on miR-142-5p as the most promising predic-
tive marker for gemcitabine. Also, univariate analysis of the
gemcitabine group showed that the only signiﬁcant clinical
factors were pN status (pN1 vs. pN0), and R factor (R1 vs.
R0). Multivariate survival analysis, based on the Cox pro-
portional hazard model, was performed by using miR-142-
5p expression (high versus low), pN status, and R factor.
Overall survival time was signiﬁcantly dependent on miR-
142-5p expression (Table 3, P = 0.034), but not on pN
b a FIG. 1 Correlation between
the expression levels of miR-
142-5p identiﬁed by miRNA
expression proﬁling and the
prognosis of patients with
resected pancreatic cancer in the
gemcitabine and
nongemcitabine groups. The
levels of miRNA expression
were normalized against
RNU6B. High miR-142-5p
expression was signiﬁcantly
associated with longer survival
times in the gemcitabine group
(P = 0.0077), but not in the
nongemcitabine group
(P = 0.48)
a b FIG. 2 The correlation
between the expression levels of
miR-204 identiﬁed by miRNA
expression proﬁling and the
prognosis of patients with
resected pancreatic cancer in the
gemcitabine and
nongemcitabine groups. The
levels of miRNA expression
were normalized against
RNU6B. High miR-204
expression was signiﬁcantly
associated with longer survival
times in the gemcitabine group
(P = 0.0054), but not in the
nongemcitabine group
(P = 0.15)
TABLE 2 Correlation between median overall survival and micr-
oRNA expression in patients with resected pancreatic cancer
Factor Overall survival (95% CI) P value
High Low
miR-142-5p
Gem group 45 (23–) 16.3 (12–23) 0.0077
Non-Gem group 13.07 (4.7–43) 11 (7.7–14.7) 0.4880
miR-204
Gem group 33 (13.27–) 16.3 (12–23) 0.0054
Non-Gem group 13.07 (8.47–26) 9 (4–14.7) 0.1527
miR-125a
Gem group 30.17 (19–) 14.57(12–31) 0.0854
Non-Gem group 12 (8.47–16.93) 14(3–) 0.8990
miR-34a
Gem group 27 (20.87–47.9) 16.3 (12–) 0.1754
Non-Gem group 16.9 (9–24.4) 8.5 (3–12) 0.0127
CI conﬁdence interval, Gem gemcitabine
miRNA and Gemcitabine Response 2385status (P = 0.24) or R factor (P = 0.11). In the gemcita-
bine group, miR-142-5p expression was an independent
prognostic marker for pancreatic cancer patients, with a
relative risk of 3.109 (Table 3).
Univariate analysis of the nongemcitabine group
showed that the only signiﬁcant clinical factor was pN
status. Therefore, multivariate survival analysis was per-
formed by using miR-34a expression and pN status. The
results show that the overall survival time was signiﬁcantly
dependent on both miR-34a expression and pN status
(Table 4, P = 0.0103 for miR-34a; P = 0.0035 for pN
status). In the nongemcitabine group, miR-34a expression
was an independent prognostic marker for pancreatic can-
cer patients with a relative risk of 2.920 (Table 4).
DISCUSSION
The present miRNA proﬁling study using two gemcit-
abine-resistant pancreatic cancer cell lines and their parent
cell lines identiﬁed 24 miRNAs candidates, which were up-
or downregulated in gemcitabine resistant cells. The pres-
ent results also showed that high miR-142-5p and miR-204
patients had statistically signiﬁcantly longer survival times
than the low miR-142-5p and miR-204 patients in the
gemcitabine group, but not in nongemcitabine group,
although further examination is needed because the number
of patients in the nongemcitabine group is too small to
conclude that there were no differences in survival between
high and low expression patients in the nongemcitabine
group. Liu et al. reported that miR-142-5p was repressed in
human lung cancer, and the transfection of miR-142-5p
signiﬁcantly repressed lung cancer cell growth.
27 miR-204
has been also reported to be downregulated in intrahepatic
cholangiocarcinoma, and the level of miR-204 expression
was inversely correlated with that of Bcl-2 expression,
possibly leading to chemotherapeutic drug-triggered
apoptosis.
28 Taken together, these data suggest that miR-
142-5p and miR-204 are promising predictive markers for
chemotherapeutic responses in patients with resected pan-
creatic cancer.
In neuroblastomas, miR-34a was generally expressed at
lower levels in unfavorable primary tumors, and the rein-
troduction of miR-34a results in a dramatic reduction in
cell proliferation.
29 miR-34a expression was decreased in 9
of 25 (36%) colon cancers, and transient introduction of
miR-34a suppressed the in vitro and in vivo growth of
colon cancer.
30 In non-small-cell lung cancer, the miR-34
family was downregulated in tumors compared with
normal tissues, and low levels of miR-34a expression
correlated with a high probability of relapse.
31 These data
suggest that miR-34a functions as a potential tumor sup-
pressor. Our results show that miR-34a is a favorable
prognostic marker in patients without gemcitabine treat-
ment after resection. We also found no correlation between
miR-34a expression and survival time in patients treated
with gemcitabine, possibly suggesting that pancreatic
cancers with low levels of miR-34a are more sensitive to
gemcitabine treatment than those with high levels of miR-
34a, although larger studies are needed to conﬁrm this.
In conclusion, miR-142-5p expression is correlated with
survival time in patients treated with gemcitabine after sur-
gical resection of pancreatic cancer, but not in patients
without gemcitabine treatment. miR-142-5p would be a
promising predictive marker for gemcitabine treatment in
patients with resected pancreatic cancer, although further
examination are needed to analyze the functional role of
these microRNAs. In the present study, we used FFPE
samples to measure the indicated miRNAs. Measurement of
such miRNAs may be possible using plasma, serum, and
pancreatic ﬂuids, suggesting that these miRNAs may be
useful in predicting the effects of chemotherapy for unre-
sectablepancreaticcancerandofneoadjuvantchemotherapy
forresectablepancreaticcancer,whereitisdifﬁculttoobtain
tissues samples without the use of invasive procedures.
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TABLE 3 Multivariate survival analysis (Cox regression model) of
clinical prognostic factors and miR-142-5p expression in patients with
gemcitabine treatment
Factor Relative risk 95% CI P value
miR-142-5p 3.109 1.087–10.01 0.0340
pN status 2.055 0.646–9.219 0.2395
R factor 2.197 0.823–5.904 0.1146
CI conﬁdence interval
TABLE 4 Multivariate survival analysis (Cox regression model) of
clinical prognostic factors and miR-34a expression in patients without
gemcitabine treatment
Factor Relative risk 95% CI P value
miR-34a 2.920 1.303–6.295 0.0103
pN status 2.957 1.410–6.812 0.0035
CI conﬁdence interval
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